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The surgical and hereditary risk factors for post-operative venous thromboembolism (VTE) are discussed and the height-
ened risk associated with particular risk factors quantified. Mechanical and pharmacological methods of prophylaxis are
described, together with the different recommendations for use with general and regional anaesthesia. Prophylaxis may
be started post-operatively and the duration of prophylaxis is discussed. The use of prophylaxis in vascular surgery is
illustrated with case examples.
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where deep vein thrombosis (DVT) in the acute phase
can embolize, a condition which is potentially fatal.
Long-term consequences are the development of
a post-thrombotic venous insufficiency, perhaps lead-
ing to venous ulceration, and chronic pulmonary
embolism with pulmonary hypertension. VTE is
a life threatening condition, as well as a disease with
chronic problems, causing suffering for the patients
and great cost for society. In Sweden with a population
of around 9 million inhabitants each year some 11,000
patients are treated for VTE, 1000 patients die from
pulmonary embolism (PE), 250,000 operations are
performed requiring prophylaxis, and 50,000 have
a post-thrombotic venous ulcer, all this costing around
100 million V. Nevertheless many doctors do not
encounter the problem very often, particularly since
fatal PE is rare, although without prophylaxis PE
would be one of the leading causes of death.
The aim of this review is to consider the contempo-
rary problems and strategies concerning the prophy-
laxis of VTE.
Risk Factor Classification
Several attempts have been made to classify patients
into different risk categories for VTE to enable the
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By giving a statistical risk estimate such classifications
can be made, although in the individual patient we do
not necessarily know if he or she would really
develop VTE. However, the prophylactic methods
available today are very safe and often inexpensive,
so treating the many to benefit a few (for instance to
prevent fatal PE) is not a major problem.
Table 1 shows one way to classify patients into var-
ious categories of risk to help in decision making
about whether or not to use prophylaxis.
Surgical risk factors
Surgery, and above all the type of surgery, is one of
the most important risk factors for VTE. The duration
of the operation as a risk factor is difficult to evaluate,
as a long duration is associated with other risk factors
related to thrombosis, such as longer time for venous
outflow obstruction, more complicated and traumatic
surgery, major blood loss and transfusion, vein
trauma etc. Some standardized orthopaedic opera-
tions, e.g. hip arthroplasty, have been used as a model
for studies of postoperative thrombo-embolic prob-
lems and prophylaxis efficacy.
The frequency of postoperative thrombosis after
neurosurgery is high. Although the surgical trauma
in itself is rather small the operation time is often
long. Neurosurgical operations have specialrved.
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ing has to be minimal.
When performing peripheral vascular surgery
pharmacological substances are generally added to
prevent arterial occlusion and those substances can
contribute to a venous thromboprophylactic effect.
Consequently information on the frequency of venous
thrombo-embolism in untreated patients is lacking.
Heparin, low molecular weight heparins, dextran
and different platelet inhibitors are often used in com-
bination. During long operations the thrombotic risk
increases because of major trauma, vascular clamping
with stasis, venous injury, frequent re-operations etc.
The frequency of thrombosis in aorto-ilio-femoral sur-
gery seems to be of the same magnitude as in other
types of major abdominal and pelvic surgery
(20e30%). The incidence of symptomatic VTE within
3 months after major vascular surgery was 1.7 to
2.8% in a population study of 1.6 million surgical pa-
tients.1 In addition, there is increasing evidence that
atherosclerosis is an independent risk factor of VTE.2
A speciality with rapidly increasing volumes is lap-
aroscopic surgery. The frequency of clinical VTE is
less than 0.5% after laparoscopic cholecystectomy.
Out-patients undergoing ambulatory surgery also
have a low risk for thrombosis with few clinically
relevant consequences.
Distal thrombosis dominates post-operatively.
Proximal thrombosis at hip arthroplasty often is local-
ized to the operated side, in the area of surgical
trauma. With phlebographic assessment, or post mor-
tem studies, it has been shown that the femoral vein is
kinked and compressed during hip surgery. It is easy
to imagine a local endothelial injury as a starting point
for these proximal thromboses. Furthermore, the ve-
nous flow diminishes during certain stages of the
operation. The highest risk for thrombosis is in the im-
mediate postoperative period, this risk decreasing
during the first postoperative week. If VTE prophyl-
axis is limited to one week post-operatively, after
major abdominal surgery as well as after hip surgery,
thrombosis can develop in up to 25% after discharge
from hospital. The most common diagnosis for
Table 1. Risk classification for postoperative venous
thromboembolism
 Low risk
- <40 years, no further risk factors
- >40 years, minor surgery
 Moderate risk
- major abdominal/pelvic surgery plus at least one further risk
factor
 High risk
- >40 years; major orthopaedic surgery or abdominal/pelvic sur-
gery for malignancyEur J Vasc Endovasc Surg Vol 33, March 2007re-admission after hip arthroplasty is VTE. It is impor-
tant to identify patients with risk of developing late
clinically relevant thrombosis and assess duration of
the prophylaxis. Local injury of the femoral vein, re-
duced venous emptying for several weeks and the
thrombogenic haemostatic activation lasting for at
least one month are three important factors for late
VTE after hip surgery. In case of malignant disorders
the disease itself is often thrombogenic.
Patients with lower leg fracture, hip fracture and
traumatic spinal injury with paraparesis have a high
risk of developing VTE. In the latter case the lack of
muscle pump function with slow venous emptying
is of pathogenic importance.
Some non-surgical and non-traumatic diagnoses
and conditions also are associated with an increased
risk of VTE such as stroke, medical intensive care,
cancer, radiation therapy. The high frequency of throm-
bosis in the paralysed leg in stroke patients illustrates,
as for paraplegia, the important function of a normal
muscle pump for venous flow. Thrombo-embolic risk
and consequently the risk of PE after stroke last
a long time. In medical in-patients history of recent
trauma, leg oedema, pneumonia and elevated platelet
count are significantly associated with VTE.3
The problem of determining the frequency of fatal
PE depends both on diagnostic difficulty and gener-
ally low autopsy rate (see Table 2). The frequency is
low in most patient groups, but PE is one of the lead-
ing causes of postoperative death. At least half of the
post-operative PE deaths occur in patients with other-
wise good prognosis. PE also is an important cause of
death in some non-surgical conditions such as stroke,
spinal injury and infection in the respiratory organs.
Risk factors for development of venous thrombosis
The pathogenesis of DVT is multifactorial with interac-
tion between hereditary and acquired risk factors. A
statistically significant relationship with a single risk
factor does not necessarily indicate a causal connec-
tion. Several risk factors in combination often are
needed for thrombosis to develop. Many patients
Table 2. The frequency of fatal pulmonary embolism without
prophylaxis
Surgery Frequency in %
General surgery 0.5e1.0
Hip arthroplasty 0.1e0.4
Hip fracture surgery 3.6e12.9
Laparoscopic cholecystectomy 0.02
Knee arthroplasty 0.1e0.2
Pelvic fracture 0.2
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The evidence for various risk factors for post-operative
DVT has been analyzed recently and is summarised in
Table 3.4 It can be difficult to differentiate between risk
factors to decide which factors will be important in
individual patients.
Hereditary risk factors
Hereditary defects in the haemostatic system have
been identified as a cause of VTE (Table 4). Consider-
ation needs to be given to the prevalence as well as to
the relative risk of mutations in causing thrombosis.
For instance, lack of protein C is a strong factor pre-
disposing to thrombosis, but this is rare. In contrast,
a high level of factor VIII is common but only in-
creases risk slightly. Some defects such as activated
protein C-resistance show great geographical and
ethnic variations. As each genetic defect is an inde-
pendent risk factor for thrombosis a person with
multiple defects has a considerably increased risk.
Usually, the more common a hereditary risk factor
is, the weaker it is, and only a few persons with this
risk factor will develop thrombosis. Half of the diag-
nosed VTE events in patients with hereditary throm-
bophilia are cause by occasional provocation and
these events could be avoided with short term,
targeted prophylaxis.
Thromboprophylactic Methods
General methods
Few general methods have been properly evaluated in
randomized studies. These general methods include
good quality medical care and nursing for the patient
e.g. atraumatic surgery, optimal fluid replacement and
early mobilization.
Specific methods
The specific methods can be divided into mechanical
and pharmacological ones. Different combinations
Table 3. Risk factors for postoperative thromboembolism
Type of surgery Hormone replacement therapy
Age Contraceptive pills
Obesity (BMI >30) Malignancy
Varicose veins Thrombophilia*
Immobilization
Previous venous thromboembolism
*Factor V Leiden mutation.are possible, but studies on combined prophylaxis
are few.5
Mechanical methods
The aim of mechanical methods is to stimulate empty-
ing from calf veins, which is considerably slower
when the patient is under anaesthesia and the calf
muscle pump non-functioning. The mechanical
methods are of different types. Both active and pas-
sive foot pedals make the calf muscles to contract. Dif-
ferent pump systems with external compression have
similar effects. Compression systems can be applied
to the sole of the foot to empty venous plexa or
muscles can be stimulated to contract by electric
stimulation.
Graded compression stockings with correct size
and application will increase the blood flow velocity
in the veins. Knee- and full leg stockings seem to
have equivalent effect in reducing venous stasis.
Knee stockings are easier to use and more comfort-
able. There is level 1 evidence for the effectiveness
of graded compression in thromboprophylaxis, but
the protection against fatal PE has not been studied
in large enough studies. This also is true for intermit-
tent pneumatic compression. However, in patients
with arterial insufficiency graded compression stock-
ings may provoke ischaemic wounds and gangrene
and if arterial insufficiency is suspected ankle pres-
sures should be measured before deciding on the
best mechanical method of thromboprophylaxis.
In operations where even a minor bleeding risk
must be avoided, i.e. in neurosurgical operations
and in head and spinal trauma, mechanical methods
may be useful.6
Pharmacological methods
Vitamin K-antagonists. The anti-coagulant effect of
vitamin K-antagonists is ascribed to the blocking of
hepatic synthesis of the normal coagulation factors
II, VII, IX and X. There are several oral vitamin K-
inhibitors. The effect of warfarin is predictable and
bioavailability good. It is available for parenteral ad-
ministration but the oral form dominates treatment
protocols. Warfarin is metabolised by the P450-system
in the liver, and hence it is susceptible to numerous
drug interactions, both beneficial and adverse. Even
food containing phyllokinons influences the anticoag-
ulant effect. Elderly patients appear more sensitive to
warfarin or at least have a higher risk for bleeding.
Prophylaxis against postoperativeVTEwith vitamin
K-antagonists is possible but three factors speak againstEur J Vasc Endovasc Surg Vol 33, March 2007
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Prevalence in the
population (%)
Prevalence in
patients with DVT (%)
Prevalence at
recurrent DVT (%)
Risk increase for venous
thromboembolism
Insufficiency of antithrombin 0.02e0.2 1 0.5e0.7 >15 fold
Insufficiency of protein C 0.2e0.4 3 1e9 w10 fold
Insufficiency of protein S 0.2 1e2 1e13 w10 fold
APC-resistance 51 20 50 w8 fold
Protrombin G20210A 21 6 2e3 fold
High concentration of factor VIII 11 25 w6 fold
Hyperhomocysteinaemia (age dependent) 5 10e15 3e4 fold
Contraceptive pills 6 20 4 fold
Previous DVT 2 14 8 fold
1 Great variations between populations.its general use: need for monitoring, risk of bleeding
and potential interactions.
Glycosaminoglycans. Heparin and heparin derivatives
such as low molecular weights heparins (LMWH)
and heparan sulphates are a mixture of sulphated an-
ionic polysaccharides and with alternate D-glucos-
amines and uronic acid. The derivation of these
substances may cause problems in some ethnic and
religious groups. For instance, in Europe pig mucosa
has been used for heparin production and bovine
lung tissue in the USA.
The principal anticoagulant effect of heparin arises
from a unique pentasaccharide sequence which binds
anti-thrombin and can be found in one third of
unfractionated heparin. When heparin binds to
anti-thrombin a configuration change is induced
which accelerates the capacity of anti-thrombin to
inactivate different coagulation enzymes: thrombin,
factor Xa and factor IXa. After the complex binding
between anti-thrombin and these enzymes, heparin
is released and can function again. Heparin with
less than 18 saccharide units cannot bind thrombin
and anti-thrombin at the same time and consequently
does not function as a accelerant in this reaction,
although the inhibitor effect on factor Xa remains.
Unfractionated heparin is heterogenous with
respect to molecular weight, anticoagulant activity
and pharmacodynamic effects. The mean molecular
weight is around 12,000e15,000 daltons. Heparin
has to be given as an injection, intravenously or sub-
cutaneously. Bioavailability has considerable individ-
ual variations and varies with dose. Unfractionated
heparin binds to several plasma proteins which
reduces the bioavailability, and contributes to the
inter-individual anticoagulant effect and heparin
resistance. Heparin also binds to macrophages and
endothelial cells. The biological half life is around
30e150 minutes, depending on the dose. With unfrac-
tionated heparin post-operative thrombosis can be
prevented effectively with reduction in the risk ofEur J Vasc Endovasc Surg Vol 33, March 2007PE, fatal PE and total peri-operative mortality. In
a meta-analysis Collins and co-workers7 collected 62
studies in general surgery, urology and orthopaedic
surgery where subcutaneous unfractionated heparin
(5000 IE 2 or 3 times daily) was compared with
untreated control groups. Prophylaxis reduced the
incidence of fatal PE (0.8e0.3%), symptomatic PE
(2.0e1.3%), asymptomatic DVT (22e9%) and total
mortality (4.2e3.3%).
Heparin has pharmacokinetic, biophysical as well
as biological limitations. The first limitation is plasma
protein binding. The biophysical limitation is due to
the fact that the heparin-anti-thrombin complex can-
not inactivate thrombin bound to fibrin and factor X
bound to phospholipids within the prothrombinase
complex. The biological limits are due to bleeding
complications, thrombocytopenia and osteoporosis.
LMWHs are also heterogeneous with respect to
molecular weight and anticoagulant effect. The
mean molecular weight varies from 4000 to 5000 dal-
tons. There are several ways to produce LMWH. Frag-
mentation can be induced by chemical reaction or by
bacterial heparinase. Different LMWHs show varia-
tions in biochemical and pharmacological qualities,
and each one is considered as a unique substance by
regulatory authorities.
LMWHs, in comparison to unfractionated heparin,
have reduced binding to:
a. plasma proteins giving more consistent dose-
response effects and better bioavailability.
b. macrophages and endothelial cells which pro-
longs plasma half life
c. platelets
d. osteoblasts
LMWH excretion is mainly renal, with prolonged
half life in patients with renal insufficiency. LMWHs
have been evaluated in many studies regarding the
prophylactic effect in patients with increased risk for
VTE.8 In most studies unfractionated heparin has
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fective as unfractionated heparin for thromboprophy-
laxis. Both treatments reduce the risk of VTE in
general surgery by at least 60%. The prophylactic ef-
fect on PE seems even better with LMWH. LMWH
can be administered subcutaneously once daily, com-
pared with the need to administer heparin twice or
three times daily. Most studies have investigated the
prophylactic effect of LMWH given for a period of
one week. There is some evidence that shorter pro-
phylaxis, for instance 1e2 days, is not as effective.
The main side effects of heparin (bleeding, heparin
induced thrombocytopenia and osteoporosis) are less
frequent with LMWH. The bleeding risk is dose
related. In a recent systematic review with 33,813
patients concluded that most patients undergoing
general surgery could receive prophylaxis safely.9
Specific thrombin inhibitors and inhibitors of activated
factor X. Today, factor Xa and IIa inhibitors are major
targets for antithrombotic drug design. The role of
thrombin in the haemostatic system is complex.
Thrombin controls several important functions and
is part of the final step in coagulation when fibrinogen
is converted into fibrin. Thrombin activates factor XIII,
which stabilises the fibrin clot and makes it resistant
to thrombolysis. Thrombin is very potent at inducing
platelet aggregation. It also prevents coagulation
through a negative feedback mechanism (via throm-
bomodulin and protein C) as well as contributing to
release of t-PA from endothelial cells.
Given the key role of thrombin it is understandable
that research has focused on specific and direct
thrombin inhibition. The best known natural and
direct thrombin inhibitor, hirudin, is produced in
the leech salivary glands. Natural hirudin is a poly-
peptide with a molecular weight of about 7000 dalton.
Its inhibition of thrombin is not dependent on other
cofactors. Several synthetic low molecular direct
thrombin inhibitors are being studied at different
stages in trials. Of great clinical interest are the syn-
thetic thrombin inhibitors which can be administered
orally.
The specific pentasaccharide sequence of heparin
which binds to antithrombin has been synthesized
(Fondaparinux) and acts as a selective, potent, indi-
rect antithrombin-dependent inhibitor of factor Xa.
The clinical thromboprophylactic effect has been stud-
ied in orthopaedic surgery (hip fracture, elective hip
arthroplasty, elective knee surgery) and once in major
abdominal surgery.10 Apart from its thromboprophy-
lactic effect the studies are of theoretical interest
because they show that isolated inhibition of factor Xis sufficient to prevent thrombosis. A large number of
direct factor Xa inhibitors are under development.
Thromboprophylaxis to Different
Patient Categories
General surgery
In most studies unfractionated heparin, or in recent
years LMWH, has been proven to be effective for
DVT as well as for PE. LMWH seems the better of
the two for prevention of embolism. Both methods
have a dose-related bleeding risk. At surgery for
malignant diseases (abdomen, pelvis) a higher dose
is more effective than a low dose, without increasing
the bleeding risk. Body weight adjusted dose does
not give any advantages.
During the past years the frequency of laparoscopic
surgery has increased dramatically. Prophylaxis has
been introduced without studying the scientific
need. The risk of clinically relevant VTE is small
and prophylaxis should probably be given only in
the presence of other risk factors.11
Orthopaedic surgery
In major orthopaedic surgery (hip and knee arthro-
plasty, hip fracture surgery and spinal surgery)
LMWH remains effective although the frequency of
thrombosis is high even with adequate prophylaxis.
Higher doses are used than in general surgery (apart
from cancer surgery). An increased bleeding risk has
not been shown. Fondaparinux seems to have a better
effect than LMWH, at least as far as phlegographically
detected DVT is concerned.
Neurosurgery
In neurosurgery mechanical prophylactic methods
dominate in many countries due to fear for bleeding
complications with pharmacological methods. How-
ever, LMWH has a good effect with little risk of bleed-
ing intra- or postoperatively.
Vascular surgery
There have been four small randomized clinical trials
of prophylaxis against VTE after arterial surgery.12e15
All patients received intravenous heparin during the
procedure. The results are not consistent but the
effects are small, probably because the patients are
given several other antithrombotic substancesEur J Vasc Endovasc Surg Vol 33, March 2007
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couraged to make VTE prophylaxis decisions based
on individual patient risk factors or on local hospital
policy. Some clinical situations are given to exemplify
and help in this decision, although strict scientific
evidence is lacking and many of the recommenda-
tions are based on extrapolations from other types of
surgery together and informed opinion. Patients
undergoing aortic repair should receive heparin, not
to increase patency but to diminish the risk of postop-
erative myocardial infarction.16 At the same time it is
reasonable to assume a prophylactic effect against
VTE. Patients with thrombophilia (see Table 4) should
be given prophylactic LMWH, irrespective of type of
vascular reconstruction. Patients with peri-operative
development of stroke and expected long-term immo-
bilization should be considered for prolonged pro-
phylaxis below knee stockings and LMWH if there
is but trivial risk of bleeding.
Acutely ill general medical patients
In three recent placebo-controlled studies with several
thousand of patients17e19 it has been shown that either
LMWH or Fondaparinux are well tolerated and pro-
vide effective thromboprophylaxis. In the MEDENOX
study17 the reduction of venographic DVT was 63%,
in the PREVENTstudy18 the reduction of the composite
of clinical VTE, sudden death and proximal DVT by ul-
trasonography was 44% and in the ARTEMIS study18
venographic DVT and symptomatic VTE was reduced
with 47%. More studies are urgently needed to further
analyze clinical relevance of thromboprophylaxis in
acutely ill medical patients.
Acute myocardial infarction
Several old and small studies showed that unfractio-
nated heparin reduces the risk and mortality of PE
and asymptomatic DVT after myocardial infarction.
With modern heart infarction care there have been
many changes which could favour thrombopro-
phylaxis (rapid mobilisation, thrombolysis, platelet
inhibitors, LMWH etc.) and an evaluation of the
thromboprophylactic effect of LMWH is lacking.
Acute ischemic stroke
LMWH in high prophylactic doses diminishes the risk
of PE and DVT but simultaneously increases the risk
for serious bleeding.Eur J Vasc Endovasc Surg Vol 33, March 2007Start of Prophylaxis
When low dose unfractionated heparin was intro-
duced some 40 years ago prophylaxis started at pre-
medication around 2 hours before surgery. This was
practical since the risk period for DVT was known
to be during the surgical procedure, with immobili-
zation, defective calf muscle pump and activated co-
agulation. This approach has a somewhat increased
risk of peri-operative bleeding, which made Ameri-
can surgeons reluctant to start preoperative prophy-
laxis. In several American studies it was shown that
starting prophylaxis post-operatively was possible,
with reasonably good effect. However, a randomized
trial then showed that pre- and postoperative start
of the LMWH dalteparin had the same effect.20 A
systematic review supported this finding, showing
that the optimal start time for prophylaxis was
between 2 hours preoperatively and 10 hours post-
operatively.21 When Fondaparinux was introduced,
it was started 6e8 hours postoperatively with excel-
lent effect and low bleeding risk.
Duration of Prophylaxis
In most studies the prophylactic duration has been
around one week. Today there are data indicating
that prolonged prophylaxis (around 1 month) gives
better effect after certain types of surgery. In elective
hip surgery there is now evidence from ameta-analysis
that prolonged prophylaxis with LMWH significantly
reduces the incidence of both phlebographic asymp-
tomatic DVT and clinically symptomatic VTE.21 The
correlation between reduction of asymptomatic throm-
bosis and clinical thromboembolism is good. Prolong-
ing prophylaxis in elective hip surgery does not
increase the bleeding risk. One recent study has shown
prolonged Fondaparinux prophylaxis to be beneficial
in hip fracture surgery.22 Another group where
prolonged prophylaxis could be of value is patients
operated on for abdominal or pelvic malignancy. In
a double-blind study of cancer surgery patients the
frequency of phlebographic thrombosis was reduced
from12 to 5%whenprophylaxiswith the LMWHenox-
aparin was prolonged from 1 week to 1 month.23 In
another recent open study a similar effect was obtained
with the LMWH dalteparin in major abdominal
surgery, reducing the frequency of phlebographic
thrombosis from 16 to 7%.24 Many questions remain
to be answered regarding prolonged prophylaxis, i.e.
the definition of risk groups (including patients not
undergoing surgery), optimal duration, the value of
oral thrombin inhibition and health economic
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potential benefit of prolonged prophylaxis in acutely
ill high risk non-surgical patients.25
Thromboprophylaxis and Regional
Anaesthesia
A special situation arises when the combination of
LMWH and spinal/epidural anaesthesia may cause
a spinal/epidural haematoma with residual neuro-
logical sequelae. Low dose unfractionated heparin
has been used without restrictions in patients who
have been operated on under spinal anaesthesia.
One case from 1989 of a possible connection
between LMWH and epidural/spinal bleeding
commenced a debate on the suitability of this com-
bination. The incidence is probably low and must
be put in the context of the incidence of haema-
tomas in patients without any pharmacological hae-
mostatic influence undergoing spinal anaesthesia.
The figures vary between 0.5 and 4.5 of 100,000
spinal anaesthetics and 0.7 and 5.2 of 100,000 epi-
dural anaesthetics.
The dominating risk factors for spinal/epidural
bleeding are:
 Anatomic risk, i.e. spinal deformation, presence of
vascular tumour, vascular anomaly etc.
 Presence of haemostatic defects (hereditary or
acquired disease, haemostasis influencing
pharmaceuticals)
 Complicated puncture or catheterisation (techni-
cally difficult puncture, several puncture trials,
bloody tap).
One problem with a complication of such low inci-
dence (also likely to occur in the absence of LMWHs)
is that a randomized trial will never be performed,
since it would require a very large sample size. Nev-
ertheless it is important to obtain an understanding
of the problem from available data and ensure that
all cases are reported to facilitate this.
According to the seventh ACCP Consensus Confer-
ence on Antithrombotic Therapy26 LMWH in combi-
nation with spinal anaesthesia can be used if some
precautions are taken:
 Spinal anaesthesia should be avoided in patients
with clinical bleeding disease.
 In patients given substances which affect haemo-
stasis (i.e. acetylsalicylic acid or other platelet
inhibitors) puncture should be performed whenthe anticoagulant effect is minimal (usually
8e12h after injection of prophylactic LMWH).
 In cases of puncture bleeding prophylactic LMWH
should be avoided.
 Removing an epidural catheter should be per-
formed at lowest LMWH levels, i.e. immediately
before the next injection.
 Prophylaxis with LMWH should not be given
less than 2 h after puncture or removal of the
catheter.
Summary
Today it is possible to define certain risk groups for the
development of venous thromboembolism (VTE),
most studies having been made on post-operative
VTE. Nonetheless, the risk classification is inexact
and many patients are given prophylaxis when they
never would have developed VTE. However, the cur-
rent prophylactic methods are safe and therefore can
be used in the post-operative situation. The dominat-
ing pharmaceutical agents are unfractionated heparin,
low molecular weight heparins and the pentasacchar-
ide Fondaparinux and are usually given for 1 week
after surgery. In some situations (elective hip surgery,
probably hip fracture surgery and in many cases oper-
ation for malignant diseases within the abdomen/
pelvis) extended prophylaxis to 1 month should be
considered. Today, there are several guidelines, which
should be used when deciding on prophylaxis.26,27
Moreover, a computer-alert program may help with
compliance and thereby reduce the risk for VTE.28
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